Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.

Goddard, NL; Cooke, MC; Gupta, RK; Nguyen-Van-Tam, JS; (2007) Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiology and infection, 135 (1). pp. 159-62. ISSN 0950-2688 DOI: https://doi.org/10.1017/S0950268806006601

Text - Published Version
License: Copyright the publishers

Download (101kB) | Preview


Respiratory syncytial virus (RSV) infection produces more severe disease and increased hospitalization rates in high-risk babies. The monoclonal antibody palivizumab offers protection against complications, and the first of five monthly doses should be administered before the onset of community RSV activity. However, the required real-time prediction of this onset is problematic. We attempted to identify seasonal RSV patterns by retrospectively examining 10 years of laboratory reports for RSV and clinical episode reports for certain respiratory presentations in both primary and secondary care. Analysis of hospital laboratory reports, incidence of acute bronchitis in primary care, and hospital admissions for acute bronchitis and bronchiolitis in young children revealed a consistent increase in RSV activity during week 43 each year. Promptly commencing prophylaxis during the second week of each October (week 42) would precede the onset of the RSV season in the United Kingdom, and provide coverage until its decline in mid-March.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
PubMed ID: 16753078
Web of Science ID: 243469700022
URI: http://researchonline.lshtm.ac.uk/id/eprint/2318


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item